Reflux inhibitors: a new approach for GERD?

Area of Science:

• Gastroenterology and Pharmacology
• Gastroesophageal Reflux Disease (GERD) Pathophysiology

Background:

• Proton pump inhibitors (PPIs) provide insufficient symptom control for a significant number of GERD patients.
• Ongoing reflux of both acid and non-acid material, often linked to transient lower esophageal sphincter relaxations (TLESRs), is a likely cause of persistent symptoms.
• Targeting TLESRs represents a potential therapeutic strategy to improve GERD management.

Purpose of the Study:

• To explore novel pharmacological approaches for GERD treatment by focusing on reflux inhibition.
• To evaluate the potential of drugs targeting TLESRs to reduce reflux events and associated symptoms.
• To assess the viability of new drug classes as an alternative or adjunct to current GERD therapies.

Main Methods:

• Investigated the role of GABA(B) receptor agonists (e.g., Baclofen) in reducing TLESRs, reflux, and symptoms.
• Examined the potential of peripherally acting GABA(B) agonists to mitigate central side effects.
• Explored the efficacy of metabotropic glutamate receptor 5 (mGluR5) antagonists in reducing TLESRs and reflux.

Main Results:

• Baclofen, a GABA(B) agonist, demonstrated reduction in TLESRs, reflux, and symptoms, but with significant central side effects.
• Peripherally acting GABA(B) agonists are under investigation for similar efficacy with potentially fewer side effects.
• mGluR5 antagonists have shown potential in reducing TLESRs and reflux.

Conclusions:

• Drugs targeting TLESRs offer a promising new avenue for managing GERD symptoms unresponsive to PPIs.
• Further clinical trials are necessary to validate the efficacy and safety of these novel reflux inhibitors.
• Reflux inhibitors targeting TLESRs may represent a significant advancement in the treatment of GERD.